
Chengdu-based Beyang Therapeutics Secures $30 Million in Series A Funding
Beyang Therapeutics has closed an oversubscribed $30 million Series A round to accelerate its AI-driven drug discovery efforts. The funding, co-led by Legend Capital and Shanghai Healthcare Capital, will fuel the development of the company’s ExCEED platform and push two key drug candidates into advanced clinical stages.




















